Delaware Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• COMBINE-AF: Extracranial Bleeding Common With OAC in AFib Treatment
  Clinically relevant extracranial bleeding affected approximately one in four patients receiving oral anticoagulation (OAC) for atrial fibrillation (AFib) over two years, potentially providing a more comprehensive measure of bleeding burden than major bleeding alone, according to a recent COMBINE-AF analysis published in Circulation.
• Long-Term ASCVD Risk Drives Expanded Statin Eligibility By 2026 Dyslipidemia Guideline
  Nearly 25 million more adults in the U.S. are eligible for statin therapy, based on recommendations in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, compared with the previous guideline, according to original research published Aug. 12 in JACC.
• CMS Proposes Updates to Ambulatory Specialty Model For HF
  The Centers for Medicare and Medicaid Services (CMS) has proposed several changes and clarifications to the Ambulatory Specialty Model (ASM) for heart failure (HF) in the 2027 Medicare Physician Fee Schedule proposed rule.
• Eagle's Eye View: Lifestyle Intervention Benefits Health Status in ANOCA Patients
  In this week’s View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients.
• MERCURI-2: Dapagliflozin Before Cardiac Surgery Lowers Postoperative AKI Risk
  Starting dapagliflozin one day before elective cardiac surgery reduced the incidence of postoperative acute kidney injury (AKI) during the first seven days after surgery, according to results from the double-blind, placebo-controlled MERCURI-2 trial published July 30 in JAMA.